Finoriq research workspace
Ascendis Pharma A/S (ASND) Institutional Holdings & 13F Ownership
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing. Review ASND institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
- Company
- Ascendis Pharma A/S (ASND)
- Ticker
- ASND
- Market Cap
- $15.7B
- Latest Price
- $252.88
- Industry
- Biotech & Pharma
Ascendis Pharma A/S (ASND) Top Institutional Holders
Top current 13F holders indexed for Ascendis Pharma A/S (ASND). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Ron BaronCIK 0001017918 | $1.3M | 0.0% | Filing2026-05-15 |
| 2 | Polen Capital ManagementCIK 0001034524 | $414,459 | 0.0% | Filing2026-05-14 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.